Margaret Kaczor
Stock Analyst at William Blair
(0.58)
# 3,741
Out of 4,818 analysts
24
Total ratings
35.71%
Success rate
-19.85%
Average return
Main Sectors:
Stocks Rated by Margaret Kaczor
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| STAA STAAR Surgical Company | Downgrades: Market Perform | n/a | $17.40 | - | 2 | Feb 12, 2025 | |
| CVRX CVRx, Inc. | Upgrades: Outperform | n/a | $6.09 | - | 3 | Jan 14, 2025 | |
| CBLL CeriBell | Initiates: Outperform | n/a | $15.07 | - | 1 | Nov 5, 2024 | |
| STIM Neuronetics | Downgrades: Market Perform | n/a | $4.19 | - | 4 | Aug 12, 2024 | |
| INGN Inogen | Upgrades: Outperform | n/a | $6.91 | - | 5 | Feb 15, 2024 | |
| SKIN The Beauty Health Company | Downgrades: Market Perform | n/a | $0.95 | - | 2 | Nov 14, 2023 | |
| DVA DaVita | Downgrades: Market Perform | n/a | $138.93 | - | 2 | Sep 11, 2019 | |
| MDT Medtronic | Assumes: Market Perform | n/a | $83.72 | - | 1 | Jun 6, 2018 | |
| ABT Abbott Laboratories | Upgrades: Outperform | n/a | $129.82 | - | 3 | Jan 25, 2018 | |
| DXCM DexCom | Initiates: Outperform | n/a | $67.25 | - | 1 | Apr 27, 2017 |
STAAR Surgical Company
Feb 12, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $17.40
Upside: -
CVRx, Inc.
Jan 14, 2025
Upgrades: Outperform
Price Target: n/a
Current: $6.09
Upside: -
CeriBell
Nov 5, 2024
Initiates: Outperform
Price Target: n/a
Current: $15.07
Upside: -
Neuronetics
Aug 12, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $4.19
Upside: -
Inogen
Feb 15, 2024
Upgrades: Outperform
Price Target: n/a
Current: $6.91
Upside: -
The Beauty Health Company
Nov 14, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $0.95
Upside: -
DaVita
Sep 11, 2019
Downgrades: Market Perform
Price Target: n/a
Current: $138.93
Upside: -
Medtronic
Jun 6, 2018
Assumes: Market Perform
Price Target: n/a
Current: $83.72
Upside: -
Abbott Laboratories
Jan 25, 2018
Upgrades: Outperform
Price Target: n/a
Current: $129.82
Upside: -
DexCom
Apr 27, 2017
Initiates: Outperform
Price Target: n/a
Current: $67.25
Upside: -